HC Wainwright Has Negative Outlook of AKBA FY2026 Earnings

Key Points

• HC Wainwright lowered its FY2026 earnings estimate for Akebia Therapeutics to a loss of $0.12 per share from $0.08 previously, while maintaining a “Buy” rating. The estimate is slightly more optimistic than the $0.13-per-share consensus loss.
• Akebia’s latest quarterly results beat expectations, reporting a $0.02-per-share loss versus the projected $0.04 loss and revenue of $49.13 million against estimates of $48.85 million.
• Analyst sentiment remains mixed, with the stock carrying a consensus “Hold” rating and a $3.75 target price. Shares recently traded at $0.91, near their 52-week low of $0.82, while institutional investors owned 33.92% of the company.

Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) - Investment analysts at HC Wainwright lowered their FY2026 earnings estimates for Akebia Therapeutics in a research note issued on Thursday, August 6th. HC Wainwright analyst M. Caufield now anticipates that the biopharmaceutical company will post earnings of ($0.12) per share for the year, down from their previous estimate of ($0.08). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Akebia Therapeutics' current full-year earnings is ($0.13) per share. HC Wainwright also issued estimates for Akebia Therapeutics' Q4 2026 earnings at ($0.03) EPS, FY2027 earnings at ($0.21) EPS, FY2028 earnings at ($0.07) EPS, FY2029 earnings at $0.04 EPS and FY2030 earnings at $0.15 EPS.

Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) last posted its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.02. Akebia Therapeutics had a negative net margin of 13.54% and a negative return on equity of 88.88%. The business had revenue of $49.13 million for the quarter, compared to analysts' expectations of $48.85 million.

Several other research firms have also recently weighed in on AKBA. Wall Street Zen cut shares of Akebia Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, May 9th. Leerink Partners lowered Akebia Therapeutics from an "outperform" rating to a "market perform" rating and set a $1.00 price objective for the company. in a research note on Friday. Weiss Ratings restated a "sell (e+)" rating on shares of Akebia Therapeutics in a research report on Monday, August 3rd. Finally, Zacks Research upgraded Akebia Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Tuesday, July 7th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $3.75.

Akebia Therapeutics Price Performance

Shares of NASDAQ:AKBA opened at $0.91 on Monday. The firm has a fifty day moving average price of $1.16 and a two-hundred day moving average price of $1.26. The company has a market cap of $252.14 million, a price-to-earnings ratio of -8.27 and a beta of 0.26. The company has a debt-to-equity ratio of 0.99, a current ratio of 1.43 and a quick ratio of 1.35. Akebia Therapeutics has a one year low of $0.82 and a one year high of $3.44.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Baird Financial Group Inc. raised its position in Akebia Therapeutics by 23.0% during the first quarter. Baird Financial Group Inc. now owns 21,393 shares of the biopharmaceutical company's stock valued at $41,000 after purchasing an additional 4,000 shares in the last quarter. AQR Capital Management LLC lifted its stake in Akebia Therapeutics by 13.1% during the first quarter. AQR Capital Management LLC now owns 176,961 shares of the biopharmaceutical company's stock worth $340,000 after purchasing an additional 20,499 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Akebia Therapeutics by 9.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 137,897 shares of the biopharmaceutical company's stock worth $265,000 after purchasing an additional 11,517 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Akebia Therapeutics by 171.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,724,439 shares of the biopharmaceutical company's stock worth $5,231,000 after purchasing an additional 1,722,245 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of Akebia Therapeutics by 123.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,652,746 shares of the biopharmaceutical company's stock valued at $6,016,000 after purchasing an additional 911,585 shares during the last quarter. 33.92% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CFO Erik Ostrowski sold 56,019 shares of the stock in a transaction on Monday, June 29th. The shares were sold at an average price of $1.11, for a total value of $62,181.09. Following the transaction, the chief financial officer owned 616,616 shares of the company's stock, valued at $684,443.76. This represents a 8.33% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 4.30% of the stock is currently owned by corporate insiders.

About Akebia Therapeutics

Akebia Therapeutics, Inc, a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, is focused on the development and commercialization of therapies for patients with kidney disease. The company's lead product candidate, vadadustat, is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to treat anemia associated with chronic kidney disease in both dialysis-dependent and non-dialysis patients. Akebia's research and development efforts also extend to preclinical programs targeting nephrology and related metabolic disorders.

Since its founding in 2007, Akebia has pursued strategic collaborations to advance its clinical pipeline and expand its market reach.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source